Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
197 Clinical Paid Trials near Boston, MA
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerDarolutamide + Abemaciclib for Prostate Cancer
Boston, Massachusetts
This trial is testing a combination of two oral drugs, abemaciclib and darolutamide, with hormone therapy to treat advanced prostate cancer. It aims to find the safest and most effective dose. The study focuses on men with advanced or high-risk prostate cancer. The treatment works by blocking proteins that help cancer grow and reducing hormone levels that fuel the cancer.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Stroke, Myocardial Infarction, Angina, Others
Must Be Taking:Androgen Deprivation Therapy
9 Participants Needed
Triple Drug Combo for Breast Cancer
Boston, Massachusetts
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer.
The names of the study drugs involved in this study are:
* VS-6766
* Abemaciclib
* Fulvestrant
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Brain Metastases, Uncontrolled Hypertension, Others
Must Be Taking:GNRH Agonists
63 Participants Needed
Gene Therapy for Non-Hodgkin's Lymphoma
Boston, Massachusetts
This trial is testing UCART20x22, a treatment using modified immune cells, in patients with B-Cell Non-Hodgkin Lymphoma that has returned or resisted other treatments. The goal is to see how safe it is and how well it works.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Lymphoma, Active Infection, Cardiovascular, Others
Must Not Be Taking:Immunosuppressants, Prednisone, Others
80 Participants Needed
ZN-A-1041 Combinations for Breast Cancer
Boston, Massachusetts
This trial is testing a new drug called ZN-A-1041 to see if it is safe and effective for patients with advanced cancers that have a specific marker called HER2. The drug aims to find and destroy these cancer cells, even if they have spread to the brain.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Progressive Neurologic Impairment, Others
Must Not Be Taking:Antiepileptics, Corticosteroids
210 Participants Needed
Acetazolamide for Obstructive Sleep Apnea
Boston, Massachusetts
OSA is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness and quality of life. In particular, REM sleep is accompanied by more frequent and longer obstructive events, that yield more profound hypoxemia than during non-REM (nREM). Exaggerated OSA severity in REM is the consequence of ventilatory drive dips, particularly during phasic eye movements. Unfortunately, the leading treatment for REM and nREM OSA, CPAP-which acts to pneumatically splint the pharynx open-is intolerable for many patients. Treatment outcomes for REM OSA are burdened by further incomplete CPAP adherence later in the night, which commonly leaves REM periods undertreated. In this protocol, the investigators will test the effect of Acetazolamide on REM OSA and on ventilatory parameters such as genioglossus muscle activity and ventilatory drive.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:21 - 75
Key Eligibility Criteria
Disqualifiers:Uncontrolled Conditions, Neuromuscular Disease, Heart Failure, Others
Must Not Be Taking:Opioids, Barbiturates, Theophylline, Others
10 Participants Needed
PRO1184 for Cancer
Boston, Massachusetts
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Interstitial Lung Disease, Others
Must Be Taking:Platinum-based Chemotherapy
569 Participants Needed
Siplizumab for Type 1 Diabetes
Boston, Massachusetts
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites.
The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM.
The secondary objectives are to:
1. Assess the safety profile of siplizumab in recently diagnosed T1DM.
2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:8 - 45
Key Eligibility Criteria
Disqualifiers:Infections, Malignancy, Autoimmune Diseases, Others
Must Not Be Taking:Atypical Antipsychotics, Glucocorticoids, Others
120 Participants Needed
Doxycycline Injection for Neurofibromatosis Type 2
Boston, Massachusetts
In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if successful.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:8+
Key Eligibility Criteria
Disqualifiers:Allergy To Doxycycline, Unstable Disease, Others
Must Not Be Taking:Anticancer Therapies, Glucocorticoids
19 Participants Needed
EP0031 for Cancer
Boston, Massachusetts
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Active Infection, HIV, Others
Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers
265 Participants Needed
Peanut SLIT-Tablet for Peanut Allergy
Boston, Massachusetts
This trial tests a tablet containing small amounts of peanut protein taken under the tongue. It aims to help people with peanut allergies become less sensitive to peanuts. Participants will take gradually increasing doses to see if their tolerance improves.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:4 - 65
Key Eligibility Criteria
Disqualifiers:Eosinophilic Esophagitis, Uncontrolled Asthma, Cardiovascular Disease, Others
Must Not Be Taking:Systemic Corticosteroids
192 Participants Needed
Ribociclib + Topotecan + Temozolomide for Neuroblastoma
Boston, Massachusetts
This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 21
Key Eligibility Criteria
Disqualifiers:Heart Disease, QTc Prolongation, Others
Must Not Be Taking:CYP3A4/5 Drugs
231 Participants Needed
Immunotherapy + Chemotherapy for Pancreatic Cancer
Boston, Massachusetts
This study is being done to test the safety and effectiveness of combining domvanalimab (AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other parts of body.
This research study involves immunotherapy. Immunotherapy triggers the body's immune system to fight cancer cells.
The names of the study drugs involved in this study are:
* Domvanalimab (also known as AB154)
* Zimberelimab (also known as AB122)
* APX005M
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, HIV, Hepatitis, Others
Must Be Taking:FOLFIRINOX
46 Participants Needed
DYP688 for Metastatic Uveal Melanoma
Boston, Massachusetts
This trial is testing a new drug called DYP688 to see if it can help treat patients with specific types of skin cancer that have certain genetic mutations. The study aims to find out if the drug is safe and effective in shrinking tumors in these patients.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Other Malignancies, Active Brain Metastases, Others
Must Not Be Taking:Anticoagulants, Chemotherapy, Immuno-oncologics
66 Participants Needed
Tazemetostat + Immunotherapy for Cancer
Boston, Massachusetts
This trial tests a combination of three drugs to treat children with specific hard-to-treat cancers. The drugs work by blocking cancer growth and boosting the immune system. The study aims to find the safest dose and see if the combination is effective.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:6 - 21
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
Must Not Be Taking:CYP3A4 Agents
49 Participants Needed
VAD044 for Hereditary Hemorrhagic Telangiectasia
Boston, Massachusetts
This trial is testing a new medication called VAD044 to see if it can help adults with Hereditary Hemorrhagic Telangiectasia (HHT). The study will compare two different doses of VAD044 to check its safety and effectiveness. Participants will be assigned to one of the groups, and neither they nor the researchers will know which treatment they are receiving.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Active Infections, Others
Must Not Be Taking:Anti-angiogenics, Anticoagulants
75 Participants Needed
Onvansertib + Paclitaxel for Breast Cancer
Boston, Massachusetts
This trial is testing the safety and effectiveness of combining Onvansertib, an experimental drug, with Paclitaxel, a chemotherapy drug, in patients with advanced triple-negative breast cancer. The goal is to find the best dose of Onvansertib and see if this combination can help treat this aggressive form of cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Uncontrolled Illness, Others
Must Not Be Taking:Strong CYP3A4 Inhibitors/inducers
50 Participants Needed
JDQ443 Combinations for Advanced Cancer
Boston, Massachusetts
This trial tests JDQ443, a new drug, combined with other treatments for patients with advanced cancers having the KRAS G12C mutation. The drug aims to stop cancer growth by targeting a specific genetic fault.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiac Disease, Others
74 Participants Needed
64Cu-FBP8 PET Scan for Alzheimer's Disease
Boston, Massachusetts
This trial uses a special brain scan to detect certain protein levels in people ranging from normal cognitive function to those with Alzheimer's disease and related dementias. The scan helps researchers understand how these proteins are distributed in the brain.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Seizures, Claustrophobia, Cardiac Arrest, Others
30 Participants Needed
Rescue Pharmacotherapy for Obstructive Sleep Apnea
Boston, Massachusetts
Persistent obstructive sleep apnea (OSA) is common in people treated with mandibular advancement device (MAD) or hypoglossal nerve stimulation (HGNS). For most patients, these treatments are the last line of defense. If MAD or HGNS do not work, then patients are left to suffer the consequences of undertreated OSA. In this study, the investigators want to test the addition of a drug treatment to their regimen. Endotypes will be targeted pharmacologically with one of the following drugs: acetazolamide for a high loop gain, atomoxetine-plus-eszopiclone for poor pharyngeal muscle compensation, or trazodone for a low arousal threshold.
This aim is expected to provide treatment strategies for rescuing non-responders to MAD or HGNS therapy.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:21 - 70
Key Eligibility Criteria
Disqualifiers:Central Sleep Apnea, COPD, Pregnancy, Others
Must Be Taking:Acetazolamide, Atomoxetine, Trazodone
70 Participants Needed
Chiauranib for Advanced Cancers
Boston, Massachusetts
This trial is testing a new drug called chiauranib for patients with advanced cancers that don't respond to standard treatments. It aims to block the signals that cancer cells need to grow. The focus is on patients with small cell lung cancer that has worsened after previous treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Cardiovascular Diseases, Hypertension, CNS Metastases, Others
Must Not Be Taking:Corticosteroids, Strong CYP3A4 Inhibitors
36 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer
Boston, Massachusetts
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles.
Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Resistant Mutations, Interstitial Lung Disease, Others
Must Be Taking:EGFR TKIs
200 Participants Needed
Gene Therapy (4D-710) for Cystic Fibrosis
Boston, Massachusetts
This trial is testing a new gene therapy called 4D-710 in adults with cystic fibrosis who can't use standard treatments. The goal is to see if it is safe and effective. 4D-710 is part of a new generation of AAV vectors being developed for cystic fibrosis gene therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Mycobacterium, Aspergillosis, Others
Must Be Taking:CFTR Modulators
40 Participants Needed
4D-150 for Age-Related Macular Degeneration
Boston, Massachusetts
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+
Key Eligibility Criteria
Disqualifiers:Uveitis, Photodynamic Therapy, Others
Must Be Taking:Anti-VEGF
215 Participants Needed
Baricitinib for Alzheimer's & ALS
Charlestown, Massachusetts
This trial tests baricitinib, a pill taken daily, in people with early signs of Alzheimer's or ALS, or those at risk. The goal is to see if it can reduce harmful inflammation in the brain. Participants will take the medication for several months to check if it reaches the brain and lowers inflammation. Baricitinib is used for the treatment of rheumatoid arthritis and has shown promising preliminary data for moderate-to-severe atopic dermatitis.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Cancer, Severe Infection, Others
Must Not Be Taking:Aducanumab, OAT3 Inhibitors
20 Participants Needed
CNP-104 for Primary Biliary Cholangitis
Boston, Massachusetts
This trial tests a new drug, CNP-104, in adults with a liver disease called primary biliary cholangitis. The drug is given through a vein to check its safety and effectiveness. The study will monitor patients for a period of time.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Liver Diseases, Kidney Disease, Diabetes, Others
Must Be Taking:UDCA, OCA
42 Participants Needed
Lurbinectedin + Doxorubicin for Leiomyosarcoma
Boston, Massachusetts
This trial is testing a new drug, lurbinectedin, combined with an existing chemotherapy drug, doxorubicin, in patients with advanced leiomyosarcoma. The goal is to see if this combination is safe and more effective than doxorubicin alone. Both drugs work by damaging the DNA in cancer cells, leading to their death. Lurbinectedin is a synthetic marine-derived anticancer agent that has shown promise in treating certain types of cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Disease, Cardiomyopathy, Others
Must Not Be Taking:CYP3A Inhibitors, CYP2D6 Inducers
62 Participants Needed
STK-012 + Pembrolizumab for Cancer
Boston, Massachusetts
This trial is testing a new drug called STK-012 alone and with another medication in patients with advanced solid tumors that haven't responded to usual treatments. The aim is to find the right dose and see how well it works.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Recent Radiotherapy, IL-2/IL-15 Therapy, Others
Must Not Be Taking:Small Molecule Inhibitors
364 Participants Needed
Sirtuin-NAD Activator for Alzheimer's Disease
Boston, Massachusetts
This trial tests if MIB-626, a pill that boosts NAD levels, can cross into the brain and help people with mild Alzheimer's disease. The goal is to see if it improves brain health and reduces aging markers. NADH has been previously tested in Alzheimer's disease with mixed results, showing some cognitive improvements in some studies but not in others.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:55 - 85
Key Eligibility Criteria
Disqualifiers:Parkinson's, Alcohol Use, Major Depression, Others
Must Be Taking:Cholinesterase Inhibitors, Memantine
50 Participants Needed
ZEN003694 + Chemotherapy for Cancer
Boston, Massachusetts
This phase I/II trial tests the safety, side effects, and best dose of a new combination of drugs, ZEN003694, cisplatin, and etoposide in treating patients with NUT carcinoma (phase I), and identifies whether this combination therapy works to shrink tumor in these patients (phase II). Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certain growth-promoting proteins and may prevent proliferation of tumor cells that use those proteins for their growth. Chemotherapy drugs, such as etoposide and cisplatin, work by stopping or slowing the growth of cancer cells. Combination therapy with ZEN003694, etoposide and cisplatin may be effective in treating patients with NUT carcinoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Issues, Others
Must Not Be Taking:Anticonvulsants, Anticoagulants, PPIs, Others
55 Participants Needed
STMC-103H for Allergies
Boston, Massachusetts
This trial is testing a new treatment called STMC-103H to see if it can help prevent allergic diseases in young children. The study focuses on babies and infants who are at risk of developing allergies. The treatment aims to improve their immune system's response to allergens, potentially reducing conditions like atopic dermatitis.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:0 - 14
Key Eligibility Criteria
Disqualifiers:Congenital Abnormalities, Immune Deficiency, Others
Must Not Be Taking:Systemic Antibiotics
264 Participants Needed
Know someone looking for new options?
Spread the word